Almira Nozdrina

Almira Nozdrina

Auto-generated profile, based on publicly available information

Almira Nozdrina

National University of Pharmacy

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2024 in Фармацевтичний часопис
Verified
Journal Article
Open access
PDF file
AKA. A. Kotvitska
A. A. Kotvitska
Alina VolkovaAlina Volkova
Alina Volkova
IKIu. V. Korzh
Iu. V. Korzh
OSO. V. Sevriukov
O. V. Sevriukov
ANA. A. Nozdrina
A. A. Nozdrina
Мета роботи - аналіз впливу впровадження електронних рецептів на антибактеріальні лікарські засоби для системного застосування групи J01 на їх реалізацію з аптек на прикладі препаратів хлорамфеніколу. Матеріали і методи. Матеріалами дослідження стали нормативно-правові акти з питань регулювання відпуску антибактеріальних засобів, а також дані управлінського обліку аптек, що входять до всеукраїнських аптечних мереж та розташовані у містах, селищах та селах всіх регіонів України. Використано методи контент-аналізу, ретроспективного та статистичного аналізу, графічні методи та узагальнення. Результати й обговорення. Встановлено, що реалізація хлорамфеніколу у натуральному вимірі у 2022 р. була без суттєвих сезонних коливань, одночасно визначено, що у липні 2022 р., після анонсування МОЗ України про введення е-рецепту в рамках посилення контролю за обігом антибактеріальних засобів та висвітленню цієї новини у медіа, спостерігається суттєве збільшення реалізації хлорамфеніколу всіх виробників в усіх дозах. Крім того, у серпні 2022 р., після впровадження е-рецепту продажі хлорамфеніколу у натуральному виміру не тільки не зменшилися, але залишалися більшими, ніж у попередніх місяцях. Аналіз показника середнього обсягу реалізації хлорамфеніколу у натуральному виміру однією аптекою протягом 2022-2023 рр. показав, що у березні та квітні 2023 р. обсяги реалізації хлорамфеніколу однією аптекою збільшилися на 81% та 22,73 % відповідно порівняно з 2022 р. Висновки. За результатами аналізу визначено, що впровадження е-рецепту, як додаткового регулюючого механізму за обігом АБЛЗ для системного застосування, було малоефективним для препаратів хлорамфеніколу. Анонсування змін в організації рецептурного відпуску АБЛЗ для системного застосування призвело до спонтанного, клінічно необумовленого ажіотажного попиту серед населення на лікарські засоби даної групи, коли збільшується реалізація, в даному випадку хлорамфеніколу, яка не корелює з певним захворюванням, що підтверджено даними за минулі роки в той самий період.

12 June 2019 in Фармацевтичний часопис
Verified
Journal Article
Open access
PDF file
IKI. V. Kubarieva
I. V. Kubarieva
Alina VolkovaAlina Volkova
Alina Volkova
ANA. A. Nozdrina
A. A. Nozdrina
Мета роботи. Здійснити аналіз структури та динаміки соціально-медичних показників хронічного вірусного гепатиту С (ГС) в Україні. Матеріали і методи. У дослідженні застосовано методи маркетингового аналізу, аналітичний, порівняльний методи та узагальнення інформації. Результати й обговорення. За результатами аналізу визначено, що близько 75 % випадків хронічного ГС у світі припадає на країни з низьким і середнім рівнями доходу. В Україні реєструють близька 47 157 випадків на рік, частка ГС серед усіх захворювань в Україні складала у 2013 р.— 0,063 %, у 2017 р. – 0,087 % і має тенденцію до збільшення. Наведено результати аналізу поширення ГС в Україні. Найбільш високі показники у Запорізькій та Миколаївській областях. Розраховано середній темп приросту показників поширення, який склав 7,4 % щорічно. Проаналізовано структуру вікового розподілу захворювання, так у період 2013–2017 рр. на доросле населення припадало 98,78 % від усіх випадків, 0,31 % — на підлітків 15 –17 років і 0,92 % — на дітей від 0 до 14 років відповідно. Серед дітей віком 0–14 років визначено приріст випадків хронічного ГС на 13,25 %. Висновки. Встановлено тенденція зростання кількості випадків хронічного ГС в період 2013–2017 рр., визначено виражене збільшення питомої ваги хронічного ГС серед усіх випадків захворювань України. В усіх регіонах спостерігається зростання кількості випадків даного захворювання. Особливу увагу слід приділити регіонам з високими показниками поширення та з високими темпами росту даного захворювання. Вакцини проти ГС не існує, отже основні зусилля необхідно зосередити на профілактиці, діагностиці та лікуванні даного захворювання. У зв’язку з цим все більшої значущості набуває розробка шляхів вдосконалення комплексного надання якісної медичної та ефективної фармацевтичної допомоги хворим на ГС.

29 April 2022 in ScienceRise: Pharmaceutical Science
Verified
Journal Article
Open access
PDF file
ANAlmira Nozdrina
Almira Nozdrina
Alina VolkovaAlina Volkova
Alina Volkova
ACAlina Cherkashyna
Alina Cherkashyna
OOOlga Ovakimian
Olga Ovakimian
Viral hepatitis affects hundreds of millions of people worldwide, the most dangerous of which are hepatitis B and C. The aim of our study was to study the prevalence and incidence of HC in the world and in Ukraine, as well as approaches in pharmacotherapy of HC to further identify effective measures to eliminate HC and improve pharmaceutical supply to patients in HC in Ukraine. The materials of the study were WHO statistical reports, national country reports, national recommendations for pharmacotherapy, the analysis of which was carried out by methods of generalization of information, analytical, comparative method. Results of the research. According to the WHO segmentation, the most frequent cases of HC are found in the populations of the Nordic-Mediterranean region (15 million cases) and the European region (12 million cases). Four countries in the world account for more than 40 % of all people infected with HC, two of which are in the Nordic-Mediterranean region (Pakistan – 7.2 and Egypt – 5.6 million people, respectively). The incidence of HC in Western Europe is up to 0.5 %, while in Northern Europe it is up to 3.3 %. Currently, the highest number of first-time HC infections in 2019 was registered among the populations of Ireland, the United Kingdom and Finland. The lowest incidence rates were found in Romania, Italy and Greece. It has been established that males aged 20–45 years prevail among those infected with HC. It was found that the prevalence of HC in Ukraine in 2015 was 3 %, according to 2020 – 5 %, with the annual number of newly recorded cases of HC increases by at least 7 %. According to the gender distribution, the ratio is on average 1.3 patients among men to 1 patient among women. An analysis of international guidelines for the pharmacotherapy of HC has shown that their latest revisions contain new direct-acting antiviral drugs, namely combinations of drugs such as glecaprevir / pibrentasvir and sofosbuvir / velpatasvir. The standard of HC treatment in Ukraine, approved in January 2021, is more in line with the recommendations of the WHO (2018), AASLD (2019) and EASL (2020) than the 2016 treatment protocol. Conclusions. The annual rate of HC infection in the world remains very high and is estimated at 1.5 million people. Regular revision and updating of standards of HC treatment with the latest direct-acting antiviral drugs, annual increase in the number of people in the world and in Ukraine who receive timely diagnosis of HCV and its full treatment are effective steps to achieve the goal of eliminating viral hepatitis

31 October 2024 in ScienceRise: Pharmaceutical Science
Verified
Journal Article
Open access
PDF file
AKAlla Kotvitska
Alla Kotvitska
Alina VolkovaAlina Volkova
Alina Volkova
ANAlmira Nozdrina
Almira Nozdrina
ISIryna Surikova
Iryna Surikova
Viral hepatitis (VH) is one of the most significant medical and social problems worldwide, posing a global threat to public health. The aim of the study was to determine the socially oriented role of pharmacists in the prevention, diagnosis and treatment of patients with VH, in particular in the implementation of decentralization of VH diagnostic services in Ukraine. The study was based on statistical reports of the WHO, the Public Health Centre of the Ministry of Health of Ukraine, international WHO guidelines on the diagnosis and pharmacotherapy of viral hepatitis, and scientific publications. Results of the study. Taking into account the results of the analysis of world experience and based on the WHO Concept in cooperation with FIP ‘Seven Star Pharmacist’ and its modern interpretation, we have identified the current role of pharmacists in the prevention, diagnosis and treatment of patients with VH. Based on the recommendations of the WHO and the Ministry of Health of Ukraine, which define the pharmacist as a link in the support of pharmacotherapy for patients with VH, a model of information and advisory pharmaceutical service is proposed, which provides for the involvement of resources of the state and regional levels at the stages of need assessment, planning and control of the service, resources of health care facilities and pharmacies, and the stages of planning and implementation of the pharmaceutical service. Noting the successful international experience and peculiarities of modern pharmaceutical care provided to patients with hypertension, we propose an adapted model of patient-pharmacist-physician interaction. This model is based on the fact that the pharmacist is one of the professional implementers of the state policy on providing the population of Ukraine with medicines and medical devices, and through the implementation of interaction with the patient and the doctor, based on the basic principles we have developed. Thus, the analysis of approaches to defining the socially oriented role of pharmacists in the prevention, diagnosis and treatment of patients with hypertension has become the basis for the development of models for the provision of information and advisory pharmaceutical services and a model of patient-pharmacist-physician interaction. Conclusions. The implementation of the model of information and advisory pharmaceutical service and the model of patient-pharmacist-physician interaction in practice will facilitate the timely detection of threatening symptoms of a socially dangerous disease and, accordingly, the diagnosis of potential VH patients and their visit to a doctor and, as a result, will be a way to prevent irrational self-medication and ensure timely, economically justified pharmacotherapy for this category of patients

4 February 2026 in Social Pharmacy in Health Care
Verified
Journal Article
Open access
NSN. M. U. Sultanbaeva
N. M. U. Sultanbaeva
DSD. U. Saydalieva
D. U. Saydalieva
SUSh. Z. Umarova
Sh. Z. Umarova
ANA. A. Nozdrina
A. A. Nozdrina
Nootropic drugs are widely used to treat cognitive impairments associated with attention deficit hyperactivity disorder, dementia, Alzheimer’s disease, schizophrenia, and cerebrovascular disorders, including stroke. The growing prevalence of neurodegenerative diseases, aging population, and increased neuropsychological stress have led to a sustained rise in demand for nootropic therapy. Under these conditions, assessing the relationship between the drug registration and the actual market availability is essential for evaluating the effectiveness of pharmaceutical supply. Aim. To conduct a comparative analysis of the range of nootropic drugs registered in the State Register of Medicines of the Republic of Uzbekistan and the actual volume of these drugs introduced into the national pharmaceutical market over the period of 2014–2024. Materials and methods. Comparative, systematic, economic, and statistical methods, well as marketing research and content analysis were used in the study. Data were obtained from the State Register of Medicines, Drug Audit reports, and the reference database. The analysis covered the number of registered and marketed trade names, countries of origin, manufacturers, international nonproprietary names, dosage forms, and the physical market volume expressed in packages. Results and discussion. The results showed an almost twofold increase in the number of the registered nootropic drugs during the study period. However, only 40–55 % of the drugs registered actually entered the market, indicating a steady gap between the regulatory approval and commercialization. Since 2021, the share of domestic nootropic drugs has increased significantly, reflecting the strengthening of national pharmaceutical production. Monocomponent drugs continued to dominate the range although the share of multicomponent drugs increased. Injectable solutions accounted for the largest share of both the registered drugs and the market volume, while oral dosage forms showed a gradual growth. Piracetam and Citicoline remain the leading names although recent years have been characterized by increasing diversification towards peptide complexes and combination drugs. Conclusions. The study provides a comprehensive overview of the structure and dynamics of the nootropic drug market in Uzbekistan and can be useful for making evidence-based decisions in pharmaceutical regulation, production planning, and market strategy development.

17 November 2023 in Social Pharmacy in Health Care
Verified
Journal Article
Open access
PDF file
ANA. A. Nozdrina
A. A. Nozdrina
Alina VolkovaAlina Volkova
Alina Volkova
Aim. To analyze the state of pharmaceutical provision of patients with hepatitis B (HB) and C (HC) according to public procurement of medicines. Materials and methods. The materials of the study were data from the Prozorro Public Procurement System, the Public Health Center of the Ministry of Health of Ukraine, the State Register of Medicines of Ukraine, the Unified Clinical Protocols for Primary, Secondary (Specialized), Tertiary (Highly Specialized) Medical Care “Viral Hepatitis C in Adults” and “Viral Hepatitis B in Adults”, and the Clinical Guideline “Viral Hepatitis B”». The study used methods of content analysis, comparative analysis and logical generalization of the results using the graphical method, as well as mathematical and statistical methods of analysis. Results. It was determined that during the period of 2017-2021, the maximum expenditures for the procurement of direct-acting antiviral drugs (DAAs) was recorded in 2017 and amounted to UAH 48.4 million. The amount of procurement in 2018 was 89 % less compared to the previous year. In 2019, the maximum rate (%) of growth in the cost of purchasing medicines for the treatment of HS compared to the previous period was 401 %. In 2020-2021, there was a gradual decrease to the minimum amount of UAH 2.4 million in 2021. According to the results of the analysis of procurement of medicines for the treatment of HS in physical terms after a significant decrease in 2018, in 2019 and 2020, there was a considerable increase and the purchase of the maximum number of packages in 2020 (12 thousand); in 2021, the minimum number of medicines (1050 units) was purchased for the entire period of analysis. It was determined that the structure of public procurement in 2017 and 2018 was dominated by original medicines of the groups J05AP08 Sofosbuvir and J05AP51 Sofosbuvir and Ledipasvir. In 2017, their share in the total volume of purchases in monetary terms amounted to 96.9 %, and in 2018 – 63.9 % of the total amount. However, starting from 2019, procurement of generic drugs in these groups prevailed, which had a share of 62.8 % in 2019, 48.3 % in 2020, and 79.2 % of the total monetary value of procurement in 2021. The dominance of the number of foreign-made drugs in the structure of the purchased drug range was noted (in monetary terms, from 97.8 % of the total expenditures in 2020 to 99.98 % in 2017). Drugs of domestic production were represented by only 2 trade names (TN), namely Livel manufactured by Valartin Pharma LLC in 2017-2018 and Ribavirin manufactured by Astropharm LLC in 2018-2020. According to the results of the ABC analysis, it was proven that each year Group A included groups J05AP51 Sofosbuvir and Ledipasvir and J05AP08 Sofosbuvir (2018, 2021-Group B). Group J05AP01 Ribavirin used as adjunctive therapy for HC complications was included in group C in 2017-2021, except in 2018, when the number of drugs purchased was increased from 1 to 3 TN. The unstable nature of procurement of medicines for the treatment of HB was revealed: from UAH 18.5 million in 2017 to UAH 707.8 thousand in 2021; during the period of 2018-2020, the purchase amount averaged UAH 2.5 million. It was determined that in 2021, compared to 2017, a decrease in this indicator was recorded by more than 85 %. Less than 50 % of the country’s regions procured medicines for the treatment of HB, and only 14 regions procured medicines through a centralized mechanism. Annual procurement took place in only 5 regions, namely Vinnytsia, Zakarpattia, Ivano-Frankivsk, Kyiv and Lviv. The largest number of TN of medicines was procured by the Kyiv region (7 TN in 2017 in the amount of UAH 52.3 million and 8 TN in 2020 in the amount of UAH 22.6 million). Conclusions. Summarizing the results of the study, it should be noted that there is a clear downward trend in centralized procurement throughout the entire study period, which, when considered in the dynamics of subsequent years, cannot contribute to achieving the goals for the elimination of viral hepatitis by 2030. However, the transition to decentralized procurement and tenders through the state enterprise “Medical Procurement of Ukraine” should contribute to the opportunity to purchase the required number of courses of medicines under the state program and increase the number of people who participate in it every year.